본문 바로가기
KERD
논문KCI 등재

당뇨환자에서 발생한 돌발성 난청에 대한 스테로이드 전신 투여와 고실내 주입의 치료효과 비교

Comparison of the Efficacy of Systemic and Intratympanic Steroid Treatment on Sudden Sensorineural Hearing Loss with Diabetes

김종애|김현범|이원용|안중기|강명구|박정홍|박종률|한치성
대한이비인후과학회 (Korean Society of Otorhinolaryngology-Head and Neck Surgery)|2008.03|대한이비인후과학회지 두경부외과학 (Korean Journal of Otorhinolaryngology-Head and Neck Surgery)|제51권 제3호|pp. 227-233

1

조회

0

다운로드

4

인용

0

참고문헌

주제분류이비인후과학

초록

High dose systemic steroid therapy is currently the mainstay of the treatment for sudden sensorineural hearing loss (SSNHL). However, it makes a glycemic control worse in patients with diabetes. Intratympanic steroid injection (ITSI) can result in reduced systemic steroid toxicity and higher perilymph steroid level selectively. The purpose of this study is to compare the efficacy of ITSI (IT group) with that of systemic steroid (IV group) on SSNHL with diabetes. Subjects and Method：Thirty eight SSNHL patients who were diagnosed with diabetes were divided into the IV group (19 patients) and the IT group (19 patients). In the IV group, prednisolone was administrated intravenously for 7 days followed by tapered doses orally for 7 days. In the IT group, dexamethasone was administrated 4 times within a 2 week-period. Hearing outcome was assessed before and after treatment. Results：In the IV group, 10 patients (58.8%) showed an improvement in the pure tone audiogram (PTA), with a mean improvement of 17.6 dB (p=0.023). In the IT group, 16 patients (84.2%) showed improvement in the PTA, with the mean improvement of 25.1 dB (p=0.000). But there was no significant difference in hearing gain and the recovery rate between the two groups. And it is more difficult to control blood sugar in the IV group rather than in the IT group. Conclusion：ITSI treatment is as effective as the systemic steroid treatment for SSNHL patients with diabetes and it can avoid a significant side effect of systemic steroids. So it could be considered as an initial treatment for the SSNHL patient with diabetes. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:227-33)

Abstract

High dose systemic steroid therapy is currently the mainstay of the treatment for sudden sensorineural hearing loss (SSNHL). However, it makes a glycemic control worse in patients with diabetes. Intratympanic steroid injection (ITSI) can result in reduced systemic steroid toxicity and higher perilymph steroid level selectively. The purpose of this study is to compare the efficacy of ITSI (IT group) with that of systemic steroid (IV group) on SSNHL with diabetes. Subjects and Method：Thirty eight SSNHL patients who were diagnosed with diabetes were divided into the IV group (19 patients) and the IT group (19 patients). In the IV group, prednisolone was administrated intravenously for 7 days followed by tapered doses orally for 7 days. In the IT group, dexamethasone was administrated 4 times within a 2 week-period. Hearing outcome was assessed before and after treatment. Results：In the IV group, 10 patients (58.8%) showed an improvement in the pure tone audiogram (PTA), with a mean improvement of 17.6 dB (p=0.023). In the IT group, 16 patients (84.2%) showed improvement in the PTA, with the mean improvement of 25.1 dB (p=0.000). But there was no significant difference in hearing gain and the recovery rate between the two groups. And it is more difficult to control blood sugar in the IV group rather than in the IT group. Conclusion：ITSI treatment is as effective as the systemic steroid treatment for SSNHL patients with diabetes and it can avoid a significant side effect of systemic steroids. So it could be considered as an initial treatment for the SSNHL patient with diabetes. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:227-33)

참고문헌 (22)

  1. Habercamp TJ, "Management of idiopathic sudden sensorineural hearing loss", AM J Otol, 20(5), pp.587~595 (1999)
  2. Shikowitz MJ, "Sudden sensorineural hearing loss", Med Clin North Am, 75(6), pp.1239~1250 (1991)
  3. Jorgensen MB, "The inner ear in diabetes mellitus", Arch Otolaryngol, 74, pp.373~381 (1961)
  4. Weng SF, "Prognostic factors of sudden sensorineural hearing loss in diabetic patients", Diabetes Care, 27(10), pp.2560~2561 (2004)
  5. Niedermeyer HP, "Cortisol levels in the human perilymph after intravenous administration of prednisolone", Audiol Neurotol, 8(6), pp.316~321 (2003)
  6. Xenellis J, "Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: A control study", Otolaryngol Head Neck Surg, 134(6), pp.940~945 (2006)
  7. Choung YH, "Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss", Laryngoscope, 116(5), pp.747~752 (2006)
  8. Trune DR, "Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H", HeJ mice, 2007, pp.226(1), 209~217
  9. Trune DR, "Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear", Hear Res, 212(1), pp.22~32 (2006)
  10. Shirwany NA, "Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig", Am J Otol, 19(2), pp.230~235 (1998)
  11. Kakehaka S, "Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes", Otol Neurotol, 27(5), pp.604~608 (2006)
  12. Fetterman BL, "Prognosis and treatment of sudden sensorineural hearing loss", Am J Otol, 17(4), pp.529~536 (1996)
  13. Kim EJ, "Korean Diabetes Association. Pathogenesis of microvascular complication, Peripheral vascular disease in diabetes", pp.400~414 (2005), Korea medical publisher
  14. Costa OA, "Inner ear pathology in experimental diabetes", Laryngoscope, 77(1), pp.68~75 (1967)
  15. Rust KR, "Inner ear damage secondary to diabetes mellitus", Arch Otolaryngol Head Neck Surg, 118(4), pp.397~400 (1992)
  16. Parnes LS, "Corticosteroid pharmacokinetics in the inner ear fluids: Animal study followed by clinical application", Laryngoscope, 109(7), pp.1~17 (1999)
  17. Chandrasehkar SS, "Intratympanic dexamthasone for sudden sensorineural hearing loss: Clinical and laboratory evaluation", Otol Neurotol, 22(1), pp.18~23 (2001)
  18. Hargunani CA, "Intratympanic injection of dexamethasone: Time course of inner ear distribution and conversion to its active form", Otol Neurotol, 27, pp.564~569 (2006)
  19. Ho HG, "Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment", Laryngoscope, 114(7), pp.1184~1189 (2004)
  20. 박용수, "돌발성 난청 환자에서 고실 내 스테로이드 주입의 효과", 대한이비인후과학회지 두경부외과학, 45(12), pp.1136~1140 (2002), 대한이비인후과학회
  21. Alles MJ, "Intratympanic steroid therapy for inner ear disease, a review of the literature", Eur Arch Otorhinolaryngol, 263(9), pp.791~797 (2006)
  22. 이동희, "돌발성 난청의 지연성 호전에 관한 연구", 대한이비인후과학회지 두경부외과학, 49(7), pp.711~716 (2006), 대한이비인후과학회

관련 논문AI추천

Comparison of Intratympanic, Systemic, and Combined Steroid Therapies for Sudden Sensorineural Hearing Loss in Patients with Diabetes Mellitus강현택, 김보경, 김효준, 이세아, 이윤지, 이종대대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2019 · 제62권 제7호돌발성 난청 환자에서 전신 스테로이드 단독요법과 고실 내 스테로이드 병용요법의 치료 효과 비교이현진, 임소연, 장경일, 전은주대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2021 · 제64권 제3호저음역 돌발성 난청 환자에서 고실 내 덱사메타존 주입술 및 경구 스테로이드 병합 요법의 효과와 경구 스테로이드 복용량 조절을 위한 예비연구임길채, 최승효대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2012 · 제23권 제2호돌발성 난청 환자에서 고실내 스테로이드 주입술 시기에 따른 청력 개선 효과노경진, 박상철, 이용주, 최현승, 한수진대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2013 · 제56권 제1호고도 및 심도 돌발성 난청에 대한 고실내 스테로이드 주입술과 경구 스테로이드 병합치료의 효과김세형대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2016 · 제27권 제1호돌발성 난청에서 스테로이드 투여 방법에 따른 치료 결과의 차이김동환, 김인식, 박철원, 윤형준, 이승환, 정재호대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2017 · 제28권 제1호

이 간행물의 다른 논문 (13건)

이하선 절제술 : 양성 이하선 종양의 수술적 치료박범정pp. 212-216등골 머리가 보존된 경우에서의 이소골 재건술의 술 후 성적유창환, 김태수, 윤태현, 안중호, 김종양pp. 221-226만성 비부비동염에서 알레르기비염과 말초 호산구증다증의 의미김성완, 심주섭, 이건희, 조중생pp. 234-239반복적인 오존노출이 마우스에서 기도재형성에 미치는 영향김인중, 나기상, 한욱경, 김용민, 김효선, 김아영pp. 240-249레이저절제술을 받은 조기성문암 환자의 음성평가최소희, 한영진, 김경아, 이강대, 이형신, 홍종철, 문효성pp. 250-255
원문 보기